| Updated in 4/13/2018 11:04:58 PM |
Viewed: 326 times |
(Journal Article) |
Brain Pathology 27 (2) (2017)
Inflammasomes as therapeutic targets for Alzheimer's disease
CS White
,
CB Lawrence
,
D Brough
,
J Rivers-Auty
ABSTRACT
Abstract Alzheimer's disease is the most common form of progressive dementia, typified initially by short term memory deficits which develop into a dramatic global cognitive decline. The classical hall marks of Alzheimer's disease include the accumulation of amyloid oligomers and fibrils, and the intracellular formation of neurofibrillary tangles of hyperphosphorylated tau. It is now clear that inflammation also plays a central role in the pathogenesis of the disease through a number of neurotoxic mechanisms. Microglia are the key immune regulators of the CNS which detect amyloidopathy through cell surface and cytosolic pattern recognition receptors (PRRs) and respond by initiating inflammation through the secretion of cytokines such as interleukin-1尾 (IL-1尾). Inflammasomes, which regulate IL-1尾 release, are formed following activation of cytosolic PRRs, and using genetic and pharmacological approaches, NLRP3 and NLRP1 inflammasomes have been found to be integral in pathogenic neuroinflammation in animal models of Alzheimer's disease. Therefore, the inflammasomes are very promising novel pharmacological targets which merit further research in the continued endeavour for efficacious therapeutics for Alzheimer's disease. This article is protected by copyright. All rights reserved. 漏 2016 International Society of Neuropathology.